Screen the Healthy?

In light of a study that showed blood-based biomarkers could predict future cognitive impairment, researchers discuss statistical analyses and the problem of false positives.

Written byTracy Vence
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, CALLE EKLUND/V-WOLFBecause most clinical tests produce at least some false positives, “screening healthy people is generally a bad idea,” pharmacologist David Colquhoun from University College London wrote at his blog this week (March 10). Colquhoun was responding to recent research touting screening tests for Alzheimer’s disease, including a study published in Nature Medicine this week (March 9) that showed blood-based biomarkers could predict future cognitive impairment in asymptomatic older adults, touting greater than 90 percent accuracy. He noted that this study was affected by the “hazards” of statistics in that up to two-thirds of “positive” tests could be false.

“If your test comes out positive, your chance of actually having the disease is almost always quite small. False positive tests cause alarm, and they may do real harm, when they lead to unnecessary surgery or other treatments,” Colquhoun wrote, adding: “The test is clearly worse than useless. That was not made clear by the authors, or by the journal.”

The Daily Mirror’s Ampp3d blog elaborated on Colquhoun’s point with an infographic, depicting “how a ‘90% accurate’ Alzheimer’s test can be wrong 92% of the time.”

Indeed, The Scientist readers also discussed the statistical conclusions of this study in comments posted to our online story. “If the error rate is 10% false positives, then twice as many unaffected people will get positive diagnoses as affected ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies